Jeon SH, Ryu JS, Choi GS, Kim JS, Kwon HY, Kim MS, Nam HS, Cho JH, Kwak SM, Lee HL, Kim HJ, Hong GJ. Erlotinib induced trichomegaly of the eyelashes.
Tuberc Respir Dis (Seoul) 2013;
74:37-40. [PMID:
23390452 PMCID:
PMC3563702 DOI:
10.4046/trd.2013.74.1.37]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2012] [Revised: 07/15/2012] [Accepted: 07/16/2012] [Indexed: 11/24/2022] Open
Abstract
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many patients treated with EGFR TKIs. However trichomegaly of eyelash is rarely reported. Although trichomegaly is not a drug-limiting side effect, it could be troublesome of continuing the treatment because of cosmetic issue or eyeball irritation by long eyelashes. Therefore clinicians are needed to pay attention to this uncommon effect. We herein describe erlotinib induced trichomegaly of eyelashes in a woman with adenocarcinoma of the lung.
Collapse